Sphingomyelin-derived nanovesicles for the delivery of the IDO1 inhibitor epacadostat enhance metastatic and post-surgical melanoma immunotherapy

Epacadostat (EPA), the most advanced IDO1 inhibitor, in combination with PD-1 checkpoint inhibitor, has failed in a recent Phase III clinical trial for treating metastatic melanoma. Here we report an EPA nanovesicle therapeutic platform (Epacasome) based on chemically attaching EPA to sphingomyelin...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhiren, Li, Wenpan, Jiang, Yanhao, Tran, Tuyen Ba, Cordova, Leyla Estrella, Chung, Jinha, Kim, Minhyeok, Wondrak, Georg, Erdrich, Jennifer, Lu, Jianqin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636136/
https://www.ncbi.nlm.nih.gov/pubmed/37945606
http://dx.doi.org/10.1038/s41467-023-43079-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10636136/
https://www.ncbi.nlm.nih.gov/pubmed/37945606
http://dx.doi.org/10.1038/s41467-023-43079-4

Ejemplares similares